NYTimes.com: As 23andMe Struggles, Concerns Surface About Its Genetic Data
October 6, 2024As 23andMe Struggles, Concerns Surface About Its Genetic Data
A plummet in the company’s valuation and a recent board resignation have raised questions about the future of genetic data collected from millions of customers.
https://www.nytimes.com/2024/10/05/business/23andme-dna-bankrupt.html?smid=em-share
QT:{{”
“People don’t, I think, appreciate how large the genetic information for a person is,” Mark Gerstein, a professor of biomedical informatics at Yale University, said on Saturday.
“In theory, if there’s a mess-up with your credit card or Social Security number, you get a new one, it can be fixed,” Professor Gerstein said. “But there’s absolutely no way to get a new genome.” …
Looking at a genome can reveal a complicated structure, akin to ones and zeros of binary code, Professor Gerstein said. That might make it seem like the information is harder to glean than from a personal tech device.
“Superficially, there might be a comforting aspect to that, as opposed to if I peek in your email box,” he said. However complex the genome is, though, it can still hold sensitive private data.
“In the longer term, maybe it actually is more revealing,” he said. “}}
Look at the face I found with PimEyes! Try it yourself on PimEyes.com! | PimEyes
October 4, 2024reverse search of myself
https://pimeyes.com/en/results/XXz_241005qk6ne9wt2fybzgm392c8b3a?query=1f27030736f031038339f900707061f3
Did Apple Just Kill Social Apps? – The New York Times
October 4, 2024AI scientists are producing new theories of how the brain learns
October 4, 2024The battle over the trillion-dollar weight-loss bonanza
October 4, 2024https://www.economist.com/business/2024/03/04/the-battle-over-the-trillion-dollar-weight-loss-bonanza glp-1 agonists
QT:{{”
The drugs’ biggest impact so far, though, has been on their makers. Sales of Wegovy, developed by a Danish firm called Novo Nordisk, swelled from $876m in 2022 to $4.5bn in 2023. The company expects double that this year. Zepbound, introduced in America in November by Eli Lilly, an American pharma giant, is expected to generate $2.9bn in sales in its first full year. Bloomberg, a data provider, predicts that by 2030 yearly sales of weight-loss medications will reach a staggering $80bn, putting them among the biggest classes of drugs in history. Eli Lilly and Novo Nordisk are expected to corner more than 90% of the market (see chart 2).
“}}
How the Guinness Brewery Invented the Most Important Statistical Method in Science | Scientific American
October 4, 2024t-test by William Gosset
Life’s hidden laws: The arcane rules of evolution and how they work | New Scientist
October 4, 2024cope’s, allen’s, foster’s…
linkstream2 microblog 